Objective The world is facing an antibiotics crisis, with resistant bacteria rendering current treatments ineffective. Novel, effective solutions are urgently required for this $40bn global market. Westway Health (WWH) is based in Galway, Ireland, and is on track to become a leading veterinary antimicrobials company in the EU. It has developed an innovative, non-antibiotic technology, effective at killing all bacteria, including antibiotic-resistant bacteria like MRSA, while not inducing resistance. WWH’s lead product in development is PanaMastTM LC, a breakthrough treatment of bovine mastitis, the most economically important infectious disease affecting the dairy industry. PanaMastTM LC will represent a step change in the way that dairy farmers manage mastitis, which affects 30% of the herd annually. It will: 1. Be the world’s first non-antibiotic medicine for mastitis, offering superior clinical outcomes and significant financial gains to end-users (€150/case); 2. Reduce wastage of milk and culling of cows; (3) Improve profitability and environmental performance on European farms and dairy processing sites. The innovation directly addresses the major global problem of antibiotic resistance, while providing a sustainable animal health solution that supports production of safe and high quality food. The Phase 1 PanaMast project was successfully completed ahead of schedule and on budget. It allowed WWH to: 1. Develop a regulatory roadmap detailing all steps required to progress from current stage of development (TRL7) to first sale of commercial product (TRL8); 2. Develop a robust commercial exploitation plan for PanaMastTM LC in EU and global markets; 3. Establish key strategic relationships to assist commercialisation of PanaMastTM LCThe Phase 1 results underpin this proposed project. The Phase 2 activities (pre-commercialisation/product development/product launch and commercialisation) are designed to ensure market launch and sale of PanaMastTM LC in the EU at TRL8 by 2020 Fields of science medical and health scienceshealth sciencespublic healthnatural sciencesbiological sciencesmicrobiologybacteriologyagricultural sciencesanimal and dairy sciencedairymedical and health scienceshealth sciencesinfectious diseasesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Keywords mastitis antibiotics antibiotic replacements zero withdrawal antibiotic resistance Programme(s) H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme H2020-EU.3.2.4. - Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy H2020-EU.3.2.1. - Sustainable agriculture and forestry H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.2.2. - Sustainable and competitive agri-food sector for a safe and healthy diet Topic(s) SMEInst-07-2016-2017 - Stimulating the innovation potential of SMEs for sustainable and competitive agriculture, forestry, agri-food and bio-based sectors Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-2-2016-2017 Funding Scheme SME-2 - SME instrument phase 2 Coordinator SLAINTE BEOGA TEORANTA Net EU contribution € 2 484 466,43 Address Unit 204 business innovation centre nuig newcastle H91 Galway Ireland See on map Region Ireland Eastern and Midland Dublin Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 1 064 771,32
